membrane-proteins
(2)Company
Company
Health
Rectify Pharma bets on proteins that need a helping hand
A cystic-fibrosis lesson became a $100 million biotech bet: help faulty membrane proteins do their jobs. Rectify’s lead liver-disease candidate is now in Phase 1, with a kidney-disease partnership behind it.
biotechnology · drug-discoveryRead →
Ai · Health · Enterprise
Nabla Bio
Nabla Bio is a Cambridge, Massachusetts biotech building AI plus wet-lab technology to design antibodies and protein therapeutics from scratch. Its Joint Atomic Modeling (JAM) platform generates de novo binders against historically undruggable membrane proteins like GPCRs, and the company has signed collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth over a billion dollars in potential payments.
ai-protein-design · antibody-designRead →